From Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in section 1A: 12709
Words on compulsory licenses: 396
ITEM 1A. RISK FACTORS
From Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 1314
Compulsory licensing of patents: 0
Item 1A.RISK FACTORS
From Roche’s Risk Management and Compliance site, section on Risk Factors, dated May 2012.
Number of words in Risk Factor document: 360
Compulsory licensing of patents: 0
Risk factors
Principal risks and uncertainties
From Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10577
Compulsory licensing of patents: 43
3D. Risk Factors
From Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96
3.D Risk Factors
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading
From Bristol Myers Squibb’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item A1: 3605
Compulsory licensing of patents: 27
Item 1A. RISK FACTORS.
From Merck’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 8038
Compulsory licenses: 44
Item 1A.Risk Factors.
From AbbVie’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 11,093
Compulsory licensing of patents: 88
ITEM 1A. RISK FACTORS
From Pfizer’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item A1: 7790
Compulsory licensing of patents: 63
Counterfeit products: 126
Pricing Pressures and Government Regulation: 604
Foreign Exchange and Interest Rate Risk: 324
Global Economic Conditions: 382
Prohibition against the use of federal funds for reimbursement of erectile dysfunction medications: 50